Oxytocin and Emotion Recognition

This study has been completed.
Sponsor:
Information provided by:
University Hospital Freiburg
ClinicalTrials.gov Identifier:
NCT01216605
First received: October 6, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted
  Purpose

The present study was designed to investigate the effects of a single dose of synthetic oxytocin on facial emotion recognition in healthy adult man. Pictures of emotional faces are presented very briefly for a few milliseconds in a backward-masking paradigm in order to vary the level of awareness. In a randomized placebo-controlled between-subject design, recognition performance is compared between a drug (24 IU oxytocin) and a placebo condition. We hypothesize that oxytocin enhances emotion recognition even for facial stimuli processed with limited awareness.


Condition Intervention Phase
Health
Drug: Syntocinon 24 IU
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science

Resource links provided by NLM:


Further study details as provided by University Hospital Freiburg:

Primary Outcome Measures:
  • Performance on a facial emotion recognition task [ Time Frame: 45 min. following drug administration ] [ Designated as safety issue: No ]

Enrollment: 56
Study Start Date: November 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Oxytocin Drug: Syntocinon 24 IU
Placebo Comparator: Placebo Drug: Placebo

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males
  • 18 to 40 years of age

Exclusion Criteria:

  • Any psychiatric diagnosis life-time
  • Somatic disease
  • IQ < 85
  • Smoker
  • Psychoactive medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01216605

Locations
Germany
Department of PSychiatry University of Rostock
Rostock, D, Germany, 18055
Sponsors and Collaborators
University Hospital Freiburg
Investigators
Principal Investigator: Gregor Domes, PhD University of Freiburg
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01216605     History of Changes
Other Study ID Numbers: X01A-DO1312/1-1, DO1312/1-1
Study First Received: October 6, 2010
Last Updated: October 6, 2010
Health Authority: Germany: Ethics Committee University of Rostock

ClinicalTrials.gov processed this record on October 21, 2014